4-{4-[({3-tert-Butyl-1-[3-(hydroxymethyl) phenyl]-1H-pyrazol-5-yl } carbamoyl)-amino] -3-fluorophenoxy} - N-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer

Details for Australian Patent Application No. 2007336873 (hide)

Owner Bayer HealthCare LLC

Inventors Nagarathnam, Dhanapalan; Smith, Roger

Agent Davies Collison Cave

Pub. Number AU-A-2007336873

PCT Pub. Number WO2008/079968

Priority 60/986,773 09.11.07 US; 60/875,830 20.12.06 US

Filing date 20 December 2007

Wipo publication date 3 July 2008

International Classifications

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

A61K 31/4439 (2006.01)

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

23 July 2009 PCT application entered the National Phase

  PCT publication WO2008/079968 Priority application(s): WO2008/079968

3 November 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007336893-Quinazolines for PDK1 inhibition

2007336858-Composite vertebral spacers and instrument